{
    "name": "ferric carboxymaltose",
    "comment": "Rx",
    "other_names": [
        "Injectafer"
    ],
    "classes": [
        "Iron Products"
    ],
    "source": "https://reference.medscape.com/drug/injectafer-ferric-carboxymaltose-100066",
    "pregnancy": {
        "common": [
            "Data are insufficient to assess risk of major birth defects and miscarriage"
        ],
        "specific": [
            {
                "type": "Animal data ",
                "description": [
                    "Administration of ferric carboxymaltose to rabbits during organogenesis caused adverse developmental outcomes including malformations and increased implantation loss at maternally toxic doses of ~12-23% of the human weekly dose of 750 mg (based on body surface area)"
                ]
            },
            {
                "type": "Clinical considerations",
                "description": [
                    "There are risks to mother and fetus associated with untreated IDA in pregnancy",
                    "Untreated IDA in pregnancy is associated with adverse maternal outcomes such as postpartum anemia; adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight",
                    "Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur, which may cause fetal bradycardia, especially during second and third trimester"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Available published data on use in lactating females demonstrate that iron is present in breast milk",
            "Adverse reactions like constipation and diarrhea reported in the breastfed infants but not considered related to drug exposure ",
            "There is no information on effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypertension reported; transient elevations in systolic BP were observed and sometimes occurred with facial flushing, dizziness, or nausea; monitor patients for signs and symptoms of hypertension following the administration of the product",
                "Laboratory assays may overestimate serum iron and transferrin bound iron in the 24 hr following administration"
            ],
            "specific": [
                {
                    "type": "Hypophosphatemia",
                    "description": [
                        "Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in postmarketing setting; these cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment",
                        "Possible risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency and malnutrition; in most cases, hypophosphatemia resolved within three months",
                        "Monitor serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment"
                    ]
                },
                {
                    "type": "Serious hypersensitivity reactions",
                    "description": [
                        "Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported",
                        "Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse",
                        "Monitor for signs and symptoms of hypersensitivity during and after administration for at least 30 minutes and until clinically stable following completion of the infusion",
                        "Only administer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Hypophosphatemia",
            "percent": "13"
        },
        {
            "name": "Nausea",
            "percent": "1-7.2"
        },
        {
            "name": "Injection site reactions",
            "percent": "3-4"
        },
        {
            "name": "Hypertension",
            "percent": "1-4"
        },
        {
            "name": "Flushing",
            "percent": "0.3-4"
        },
        {
            "name": "Erythema",
            "percent": "0.3-3"
        },
        {
            "name": "Dizziness",
            "percent": "1-2.1"
        },
        {
            "name": "Hyperphosphatemia",
            "percent": "1-2.1"
        },
        {
            "name": "Vomiting",
            "percent": "0.2-2"
        },
        {
            "name": "Injection site extravasation",
            "percent": "0.2-2"
        },
        {
            "name": "Injection site discoloration",
            "percent": "1.4"
        },
        {
            "name": "Headache",
            "percent": "1-1.3"
        },
        {
            "name": "Hepatic enzyme increased",
            "percent": "1.2"
        },
        {
            "name": "Rash",
            "percent": "1-1.2"
        },
        {
            "name": "Dysgeusia",
            "percent": "1-1.2"
        },
        {
            "name": "Hypotension",
            "percent": "1"
        },
        {
            "name": "Injection site reactions",
            "percent": "8"
        },
        {
            "name": "Rash",
            "percent": "8"
        },
        {
            "name": "Headache",
            "percent": "5"
        },
        {
            "name": "Vomiting",
            "percent": "5"
        },
        {
            "name": "Nasopharyngitis",
            "percent": "3"
        },
        {
            "name": "Flushing",
            "percent": "3"
        },
        {
            "name": "Gastrointestinal infections",
            "percent": "3"
        },
        {
            "name": "Liver function test increased",
            "percent": "3"
        },
        {
            "name": "Platelet count decreased",
            "percent": "3"
        },
        {
            "name": "White blood cell count decreased",
            "percent": "3"
        },
        {
            "name": "Constipation",
            "percent": "0.5"
        },
        {
            "name": "Cardiac disorders",
            "percent": null
        },
        {
            "name": "Tachycardia",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Chest discomfort",
            "percent": null
        },
        {
            "name": "chills",
            "percent": null
        },
        {
            "name": "pyrexia",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Hypophosphatemia",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Arthralgia",
            "percent": null
        },
        {
            "name": "back pain",
            "percent": null
        },
        {
            "name": "hypophosphatemic osteomalacia",
            "percent": null
        },
        {
            "name": "rarely reported event",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Syncope",
            "percent": null
        },
        {
            "name": "Respiratory",
            "percent": null
        },
        {
            "name": "thoracic and mediastinal disorders",
            "percent": null
        },
        {
            "name": "Dyspnea",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Pregnancy",
            "percent": null
        },
        {
            "name": "Fetal bradycardia",
            "percent": null
        }
    ]
}